Document Type

Article

Disciplines

Medicine and Health Sciences

Abstract

Breast cancer is a major health concern for many women, but despite the current standard therapies, many women still die of metastatic disease. Angiogenesis has been evaluated as a possible target for therapy and bevacizumab (Avastin®, Genentech/Roche, CA, USA), a monoclonal antibody against VEGF-A, has been developed to target this. Current clinical trials utilizing bevacizumab have shown an increase in progression-free survival, but this has not translated to an increase in overall survival in breast cancer patients. In this article, we summarize the currently published trials utilizing bevacizumab in the treatment of breast cancer and describe various methods of measuring angiogenesis in vitro and in vivo. We also describe the related process of lymphangiogenesis, as this may contribute to the mechanism of cancer progression and may be a potential target for therapy in the future. Understanding these processes may help us develop new treatments for breast cancer.

Comments

Future Oncol. Author manuscript; available in PMC 2013 February 1. Published in final edited form as: Future Oncol. 2012 April; 8(4): 403–414. doi: 10.2217/fon.12.22 PMCID: PMC3464486 NIHMSID: NIHMS406021

Share

COinS